We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pharma Stock Roundup: PFE Ends Hemophilia Deal With SGMO & More
Read MoreHide Full Article
Novartis’ (NVS - Free Report) phase III study showed a positive risk-benefit profile of an investigational gene therapy candidate, intrathecal onasemnogene abeparvovec (OAV101 IT), for treating spinal muscular atrophy (SMA). Sangamo Therapeutics (SGMO - Free Report) announced that its partner Pfizer (PFE - Free Report) has decided to end their global collaboration and license agreement for giroctocogene fitelparvovec, a one-time gene therapy candidate for treating moderately severe to severe hemophilia A. The European Commission granted approval for the expanded use of J&J’s (JNJ - Free Report) drug, Rybrevant, as a combination therapy in non-small cell lung cancer (NSCLC).
Here's a recap of the week’s most important stories.
PFE Returns Rights to Hemophilia A Candidate to Partner SGMO
Sangamo Therapeutics regained development and commercialization rights for its hemophilia A candidate, giroctocogene fitelparvovec, after partner Pfizer conveyed its decision to terminate their collaboration. SGMO’s stock crashed on the news. Sangamo is considering all options to continue the program, which includes looking for a new collaboration partner for the candidate. In July, the companies announced positive data from the pivotal phase III AFFINE study on giroctocogene fitelparvovec. The study met its primary as well as key secondary endpoints.
Pfizer had in-licensed global rights to giroctocogene fitelparvovec from Sangamo in 2019 and was responsible for pivotal studies as well as regulatory and potential commercialization activities for the candidate. Sangamo said that Pfizer had informed the company of its intention to file regulatory applications for giroctocogene fitelparvovec in the United States and EU in early 2025. Sangamo was eligible to earn up to $220 million in milestone payments from Pfizer upon achieving certain regulatory and commercial milestones for giroctocogene fitelparvovec.
NVS’ Study on SMA Candidate Meets Primary Goal
Novartis’ phase III study evaluating OAV101 IT in treatment-naïve patients with SMA type 2, rare, genetic neuromuscular disease, aged two and older, met its primary endpoint. Data from the STEER study showed that treatment with OAV101 IT led to an increase from baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) total score. HFMSE is a scale that measures physical abilities in patients with SMA types 2 and 3. Novartis plans to share data from the SHEER study with the FDA and other regulatory agencies in 2025.
EU Nod for J&J’s Rybrevant-Lazcluze Combo for NSCLC
J&J announced that the European Commission has granted approval to a combination of its intravenously administered EGFR/MET inhibitor Rybrevant (amivantamab) and oral EGFR-TKI inhibitor, Lazcluze (lazertinib), for use in certain patients with EGFR-mutated non-small cell lung cancer (NSCLC). The approval is for the Rybrevant-Lazcluze combination as a first-line treatment for adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions (ex19del) or exon 21 L858R substitution (L858R) mutations. The FDA approved this combination in August for a similar indication. This approval is based on data from the phase III MARIPOSA study.
Image: Bigstock
Pharma Stock Roundup: PFE Ends Hemophilia Deal With SGMO & More
Novartis’ (NVS - Free Report) phase III study showed a positive risk-benefit profile of an investigational gene therapy candidate, intrathecal onasemnogene abeparvovec (OAV101 IT), for treating spinal muscular atrophy (SMA). Sangamo Therapeutics (SGMO - Free Report) announced that its partner Pfizer (PFE - Free Report) has decided to end their global collaboration and license agreement for giroctocogene fitelparvovec, a one-time gene therapy candidate for treating moderately severe to severe hemophilia A. The European Commission granted approval for the expanded use of J&J’s (JNJ - Free Report) drug, Rybrevant, as a combination therapy in non-small cell lung cancer (NSCLC).
Here's a recap of the week’s most important stories.
PFE Returns Rights to Hemophilia A Candidate to Partner SGMO
Sangamo Therapeutics regained development and commercialization rights for its hemophilia A candidate, giroctocogene fitelparvovec, after partner Pfizer conveyed its decision to terminate their collaboration. SGMO’s stock crashed on the news. Sangamo is considering all options to continue the program, which includes looking for a new collaboration partner for the candidate. In July, the companies announced positive data from the pivotal phase III AFFINE study on giroctocogene fitelparvovec. The study met its primary as well as key secondary endpoints.
Pfizer had in-licensed global rights to giroctocogene fitelparvovec from Sangamo in 2019 and was responsible for pivotal studies as well as regulatory and potential commercialization activities for the candidate. Sangamo said that Pfizer had informed the company of its intention to file regulatory applications for giroctocogene fitelparvovec in the United States and EU in early 2025. Sangamo was eligible to earn up to $220 million in milestone payments from Pfizer upon achieving certain regulatory and commercial milestones for giroctocogene fitelparvovec.
NVS’ Study on SMA Candidate Meets Primary Goal
Novartis’ phase III study evaluating OAV101 IT in treatment-naïve patients with SMA type 2, rare, genetic neuromuscular disease, aged two and older, met its primary endpoint. Data from the STEER study showed that treatment with OAV101 IT led to an increase from baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) total score. HFMSE is a scale that measures physical abilities in patients with SMA types 2 and 3. Novartis plans to share data from the SHEER study with the FDA and other regulatory agencies in 2025.
EU Nod for J&J’s Rybrevant-Lazcluze Combo for NSCLC
J&J announced that the European Commission has granted approval to a combination of its intravenously administered EGFR/MET inhibitor Rybrevant (amivantamab) and oral EGFR-TKI inhibitor, Lazcluze (lazertinib), for use in certain patients with EGFR-mutated non-small cell lung cancer (NSCLC). The approval is for the Rybrevant-Lazcluze combination as a first-line treatment for adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions (ex19del) or exon 21 L858R substitution (L858R) mutations. The FDA approved this combination in August for a similar indication. This approval is based on data from the phase III MARIPOSA study.
J&J announced that it is in-licensing global rights to Japan’s Kaken Pharmaceutical’s STAT6 program for autoimmune and allergic diseases, including atopic dermatitis (AD). Kaken’s STAT6 program includes lead candidate KP-723, which is expected to enter phase I studies in AD in 2025.
The NYSE ARCA Pharmaceutical Index declined 1.01% in the past five trading sessions.
Large Cap Pharmaceuticals Industry 5YR % Return
Large Cap Pharmaceuticals Industry 5YR % Return
Here’s how the eight major stocks performed in the previous five trading sessions.
Image Source: Zacks Investment Research
In the last five trading sessions, Novo Nordisk rose the most (0.2%), while Lilly declined the most (2.2%).
In the past six months too, while AbbVie rose the most (9.7%), Novo Nordisk declined the most (37.0%).
(See the last pharma stock roundup here: NVO Obesity Study Failure, FDA Nods for PFE, LLY)
What's Next in the Pharma World?
Watch this space for regular pipeline and regulatory updates next week.
J&J has a Zacks Rank #2 (Buy), while Pfizer, Novartis and Sangamo have a Zacks Rank #3 (Hold) each. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.